ANCHOR Indication For Amarin’s Vascepa Will Face FDA Panel Scrutiny

Key question at the Oct. 16 advisory committee review could be whether FDA should wait for results from an ongoing cardiovascular outcomes trial before significantly broadening the prescription fish oil product’s approval to include adults with high triglycerides and mixed dyslipidemia.